Skip to Content

Clinical Trial News

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online

Posted 4 days ago in Clinical Trials

DUBLIN, Feb. 1, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that data from the phase 3 pivotal study of defibrotide were published online in BLOOD, the Journal of the American Society of Hematology (ASH). The data demonstrated that defibrotide use in patients with hepatic veno-occlusive (VOD), also known as sinusoidal obstruction syndrome (SOS), with multi-organ failure (MOF)...

Read more...

Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial

Posted 2 weeks ago in Clinical Trials

BALTIMORE, Jan. 19, 2016 /PRNewswire/ -- Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax™-vectored Ebola virus vaccine. The vaccine is a version of the company's patented VSV vector that has been engineered f...

Read more...

Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis

Posted 3 weeks ago in Clinical Trials

CAMBRIDGE, Mass., January 15, 2016 --(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced top-line results from the Phase 3 clinical trial of its lead drug candidate, isunakinra (EBI-005), for the treatment of severe allergic conjunctivitis. In this trial, there were no...

Read more...

Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes

Posted 3 weeks ago in Clinical Trials

MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in patients with myelodysplastic syndromes (MDS). This clinical trial, also referred to as the IMergeTM study, is being conducted by Janssen Research & Development, LLC, and is the second study to be initiated under the terms of the...

Read more...

Karyopharm Initiates Clinical Trial of Oral Selinexor in Advanced Liposarcoma

Posted 3 weeks ago in Clinical Trials

NEWTON, Mass., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the initiation of Selinexor in Advanced Liposarcoma ("SEAL"), a new Phase 2/3 clinical trial with oral selinexor, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE™) compound that inhibits exportin 1 (XPO1). SEAL is a multi-center, r...

Read more...

GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

Posted 3 weeks ago in Clinical Trials

MEMPHIS, Tenn.--(BUSINESS WIRE)--Jan. 13, 2016-- GTx, Inc. (Nasdaq: GTXI) today announced the initiation of its Phase 2 clinical trial to treat postmenopausal women with stress urinary incontinence (SUI). The Phase 2 proof-of-concept study of enobosarm (GTx-024) is the first clinical trial to evaluate a selective androgen receptor modulator (SARM) for SUI. "Given the selective anabolic activity of enobosarm, we...

Read more...

AstraZeneca and Incyte Announce New Lung Cancer Clinical Trial Collaboration

Posted 3 weeks ago in Clinical Trials

11 January 2016 -- AstraZeneca and Incyte Corporation today announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso® (osimertinib). The combination will be assessed as a second line treatment for patients with EGFR mutation-positive n...

Read more...

Achaogen Announces Enrollment of First Patient in EPIC, a Phase 3 Clinical Trial for the Treatment of Complicated Urinary Tract Infections (cUTI) With Plazomicin

Posted 3 weeks ago in Clinical Trials

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, announced today the enrollment of its first patient in EPIC (Evaluating plazomicin in cUTI), a Phase 3 clinical trial of plazomicin to treat complicated urinary tract infections (cUTI)...

Read more...

Abbvie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

Posted 3 weeks ago in Clinical Trials

NORTH CHICAGO, Ill., Jan. 11, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6)...

Read more...

Roche Presents Updated Results for Investigational Cancer Immunotherapy Atezolizumab in Advanced Bladder Cancer

Posted 4 weeks ago in Clinical Trials

Basel, 8 January 2016 -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (MPDL3280A) in people with locally advanced or metastatic urothelial carcinoma (mUC). Median overall survival (mOS) in this heavily pre-treated population was 11.4 months [95% CI: 9.0, NE] in people with higher levels of...

Read more...

Abbvie Announces Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, An Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis

Posted 4 weeks ago in Clinical Trials

NORTH CHICAGO, Ill., Jan. 8, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the start of a large Phase 3 clinical trial program to study the use of ABT-494, an investigational, once-daily, oral selective JAK1 inhibitor for the treatment of rheumatoid arthritis (RA). This program will include adult patients with inadequate responses (IR) to conventional or biologic...

Read more...

ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection

Posted 4 weeks ago in Clinical Trials

London, 7 January 2016 -- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with Janssen Sciences Ireland UC (Janssen) for the phase III investigation and commercialisation of the long-acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) for the treatment of HIV-1 infection. The...

Read more...

Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection

Posted 4 weeks ago in Clinical Trials

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 5, 2016-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3 clinical trials (Studies 108 and 110) evaluating investigational use of once-daily tenofovir alafenamide (TAF) 25 mg in treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic hepatitis B virus (HBV) infection met their primary objectives. The studies ...

Read more...

Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis

Posted 4 weeks ago in Clinical Trials

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 5, 2016-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company is stopping its Phase 2 clinical study of the investigational monoclonal antibody simtuzumab among patients with idiopathic pulmonary fibrosis (IPF). This decision follows an analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC), which recommended that the...

Read more...

Merck, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

Posted 4 weeks ago in Clinical Trials

January 4, 2016 - Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T...

Read more...

Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir

Posted 5 weeks ago in Clinical Trials

DURHAM, N.C., Dec. 28, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection...

Read more...

World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing

Posted 6 weeks ago in Clinical Trials

KENILWORTH, N.J., December 23, 2015 --(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV∆G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO). According to the WHO, the EUAL process is d...

Read more...

Boehringer Ingelheim’s Third Generation EGFR TKI, BI 1482694, Receives FDA Breakthrough Therapy Designation for Treatment of Patients with Non-Small Cell Lung Cancer

Posted 6 weeks ago in Clinical Trials

Ridgefield, Conn., December 21, 2015 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational third-generation epidermal growth factor receptor (EGFR) mutant-specific tyrosine kinase inhibitor (TKI), BI 1482694 (HM61713). The designation is based on results from the Phase I/II HM-EMSI-101 clinical trial evaluating the t...

Read more...

Kadmon Corporation Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Non-Small Cell Lung Cancer with Activating EGFR Mutations and Brain Metastases or Leptomeningeal Disease

Posted 7 weeks ago in Clinical Trials

NEW YORK, December 18, 2015 – Kadmon Corporation, LLC today announced that the first patient has been dosed in a Phase 2 clinical trial of tesevatinib, the Company’s investigational tyrosine kinase inhibitor, for the treatment of non-small cell lung cancer (NSCLC) in patients who have activating mutations of the epidermal growth factor receptor (EGFR) gene, prior treatment with a tyrosine kinase inhibitor, and whose ...

Read more...

Fourth Clinical Trial Opened With Monalizumab (IPH2201)

Posted 7 weeks ago in Clinical Trials

December 17, 2015 -- Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced the opening of the Phase Ib/II trial of monalizumab (previously IPH2201), a first-in-class NKG2A checkpoint inhibitor, in combination with cetuximab in patients with relapsed or metastatic squamous cell cancer of the head and neck (SCCHN). This multicentric trial, which will include up to 70 patients, will be pe...

Read more...
Older articles
Hide